Blueprint Medicines Aims For Genomically Defined GIST Indication With Avapritinib NDA
Executive Summary
Kinome-focused Blueprint Medicines plans to follow up its first NDA, for all lines of therapy in patients with exon 18 mutant GIST or fourth-line use in non-genomically selected patients, with submissions for third-line GIST and advanced systemic mastocytosis in 2020.
You may also be interested in...
Keeping Track: Ayvakit Approval, Keytruda Supplement, NME Submissions
The latest drug development news and highlights from our US FDA Performance Tracker.
Blueprint Lays Out Path To Early Approval In Small GIST Population
Blueprint Medicines will pursue an accelerated path to approval for its newly designated breakthrough therapy BLU-285 in the treatment of gastrointestinal stromal tumors in a small subset of patients.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.